Global Retirement Partners LLC Buys 840 Shares of Sanofi SA (SNY)

Global Retirement Partners LLC lifted its stake in shares of Sanofi SA (NYSE:SNY) by 420.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,040 shares of the company’s stock after acquiring an additional 840 shares during the quarter. Global Retirement Partners LLC’s holdings in Sanofi were worth $45,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Quadrant Capital Group LLC increased its position in shares of Sanofi by 259.5% during the fourth quarter. Quadrant Capital Group LLC now owns 12,187 shares of the company’s stock worth $511,000 after acquiring an additional 8,797 shares during the period. Wetherby Asset Management Inc. increased its position in shares of Sanofi by 11.1% during the fourth quarter. Wetherby Asset Management Inc. now owns 35,988 shares of the company’s stock worth $1,563,000 after acquiring an additional 3,596 shares during the period. Employees Retirement System of Texas increased its position in shares of Sanofi by 288.2% during the fourth quarter. Employees Retirement System of Texas now owns 164,769 shares of the company’s stock worth $7,153,000 after acquiring an additional 122,327 shares during the period. Pacer Advisors Inc. increased its position in shares of Sanofi by 2.8% during the third quarter. Pacer Advisors Inc. now owns 194,889 shares of the company’s stock worth $8,706,000 after acquiring an additional 5,283 shares during the period. Finally, Garrison Financial Corp increased its position in shares of Sanofi by 8.7% during the fourth quarter. Garrison Financial Corp now owns 9,705 shares of the company’s stock worth $371,000 after acquiring an additional 775 shares during the period. 7.04% of the stock is currently owned by institutional investors and hedge funds.

NYSE:SNY opened at $44.30 on Tuesday. The firm has a market capitalization of $111.06 billion, a P/E ratio of 14.15, a price-to-earnings-growth ratio of 2.41 and a beta of 0.67. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.85 and a current ratio of 1.22. Sanofi SA has a 12 month low of $37.43 and a 12 month high of $45.62.

Sanofi (NYSE:SNY) last released its quarterly earnings data on Thursday, February 7th. The company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.01. Sanofi had a net margin of 12.20% and a return on equity of 18.18%. The company had revenue of $9 billion during the quarter, compared to the consensus estimate of $9 billion. During the same quarter in the prior year, the firm posted $1.06 earnings per share. Sanofi’s revenue for the quarter was up 3.5% on a year-over-year basis. Analysts predict that Sanofi SA will post 3.1 EPS for the current fiscal year.

The business also recently disclosed an annual dividend, which will be paid on Friday, May 31st. Shareholders of record on Wednesday, May 8th will be paid a $1.7395 dividend. The ex-dividend date is Tuesday, May 7th. This represents a yield of 4.2%. Sanofi’s dividend payout ratio is presently 38.34%.

In other Sanofi news, major shareholder Sanofi sold 131,115 shares of the company’s stock in a transaction on Friday, March 8th. The shares were sold at an average price of $412.17, for a total value of $54,041,669.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.00% of the company’s stock.

Several research firms recently commented on SNY. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating and set a $46.00 target price on the stock. in a report on Saturday, January 26th. Morgan Stanley began coverage on Sanofi in a report on Friday, December 14th. They issued an “equal weight” rating on the stock. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Sanofi in a report on Tuesday, December 4th. HC Wainwright reissued a “buy” rating on shares of Sanofi in a report on Thursday, February 28th. Finally, TheStreet lowered Sanofi from a “b” rating to a “c+” rating in a report on Thursday, February 7th. Eight investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $51.00.

COPYRIGHT VIOLATION WARNING: This story was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The correct version of this story can be viewed at https://sportsperspectives.com/2019/04/02/global-retirement-partners-llc-buys-840-shares-of-sanofi-sa-sny.html.

Sanofi Company Profile

Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

Read More: What are the most popular ETFs

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.